Current filters:


Popular Filters

6601 to 6625 of 7008 results

Added indication for Bristol-Myers’ Erbitux approved by FDA


The US Food and Drug Administration yesterday approved US drug major Bristol-Meyers Squibb’s (NYSE:…

Bristol-Myers SquibbErbituxNorth AmericaOncologyPharmaceuticalRegulation

Vertex’ Incivek set to break record for fastest product launch


Vertex Pharmaceuticals’ (Nasdaq: VRTX) new hepatitis C drug Incivek (telaprevir) is being touted…

FinancialIncivekMarkets & MarketingPharmaceuticalVertex

Novo Nordisk says DegludecPlus provides superior glycemic control vs Lantus


Denmark-based insulin giant Novo Nordisk (NVO: N) yesterday announced positive clinical results from…

DegludecDegludecPlusDiabetesLantusNovo NordiskPharmaceuticalResearchSanofi

Small-molecule cancer drug revenues set to reach $27.3 billion in 2015, predicts Visiongain


Rising disease prevalence, along with advances in pharmacotherapy and diagnostics, will stimulate the…

Markets & MarketingOncologyPharmaceutical

Study identifies factors linked with better medication response for treatment of juvenile arthritis


Among patients with juvenile idiopathic arthritis (JIA) who initiated treatment with the drug etanercept…


Pfizer returns rights to TNF-alpha targeting nanobodies to Ablynx


Shares of Belgian drug developer Ablynx [Euronext Brussels: ABLX] fell 18.2% to 2.93 euros in morning…


Teva to continue selling Viagra generic in Russia


Israel-basedTeva Pharmaceutical Industries (Nasdaq: TEVA) managed to avoid a high-profile confrontation…

DynamicoEuropeGenericsMarkets & MarketingPatentsPfizerPharmaceuticalReproductiveTeva Pharmaceutical IndustriesViagra

Takeda slashes full-year forecasts on Nycomed costs and yen strength


Takeda Pharmaceuticals (TYO: 4502), Japan’s largest drugmaker, posted flat results for the fiscal…

FinancialPharmaceuticalTakeda Pharmaceuticals

European and international experts discuss the way forward in developing ophthalmology medicines


The European Medicines Agency assembled for the first time some 200 experts in eye diseases from Europe,…


Synthes acquisition by Johnson & Johnson delayed as EU Commission starts in-depth investigation


The planned $21.3 billion acquisition of orthopedic device maker Synthes (SYST: VX), which is listed…

Johnson & JohnsonMergers & AcquisitionsPharmaceuticalSynthes

Vertex’ Kalydeco marks a milestone in fight against cystic fibrosis


The oral drug ivacaftor (VX-770) provides major, sustained improvement in lung function, growth and other…

ivacaftorKalydecoPharmaceuticalRare diseasesResearchRespiratory and PulmonaryVertex

Anti-inflammatory therapeutics market to grow to $85.9 billion in 2017


The anti-inflammatory therapeutics market accounted for $32.3 billion in 2002 from its seven major indications.…

Anti-Arthritics/RheumaticsGastro-intestinalsMarkets & MarketingNeurologicalPharmaceuticalRespiratory and Pulmonary

US FDA claims more NDA approvals than other countries, with 35 in fiscal year 2011


US FDA claims more NDA approvals than other countries, with 35 in fiscal year 2011

BiotechnologyNorth AmericaPharmaceuticalRegulation

Strong data from MDV3100 prostate cancer trial lead Medivation and Astellas to stop study early


USA-based Medivation (Nasdaq: MDVN) saw its shares rocket 120% to $36.51 in early trading yesterday,…

Astellas PharmaMedivationOncologyPharmaceuticalResearch

Sanofi files for EU approval of Lyxumia, a type-2 diabetes agent partnered with Zealand Pharma


Danish drug discovery firm Zealand Pharma (Nasdaq OMX: ZEAL.CO), says that its partner, French drug major…

DiabetesFinancialLyxumiaPharmaceuticalRegulationSanofiZealand Pharma

GlaxoSmithKline finalizes $3 billion deal with US government over marketing practices


UK pharma giant GlaxoSmithKline (LSE: GSK) said yesterday that it has reached an agreement in principle…

AvandiaFinancialGlaxoSmithKlineLegalNorth AmericaPharmaceutical

FDA panel gives unanimous backing for Merck & Co’s Vytorin for some kidney disease patients


US drug giant Merck & Co (NYSE: MRK) said yesterday that the Endocrinologic and Metabolic Drugs Advisory…

Cardio-vascularMerck & CoNorth AmericaPharmaceuticalRegulationVytorin

Amylin and Lilly’s diabetes drug Byetta has rapid, powerful anti-inflammatory effect


Byetta (exenatide), a drug which has been co-developed and now marketed by US biotech firm Amylin (Nasdaq:…

AmylinByettaCardio-vascularDiabetesEli LillyPharmaceuticalResearch

ImmuPharma’s Lupuzor OKed to start Phase III and fast-tracked by US FDA


UK-based ImmuPharma plc (LSE:IMM), which last month regained rights to its investigational lupus drug…

ImmuPharmaLupuzorPharmaceuticalRare diseasesRegulationResearch

Ipsen sells North American rights for Apokyn to Britannia Pharma


French drugmaker Ipsen (Euronext: IPN) today has sold its North American development and marketing rights…

ApokynBritannia PharmaceuticalsIpsenMergers & AcquisitionsNeurologicalPharmaceuticalSTADA Arzneimittel

Hepatitis B vaccines market forecast to show moderate growth until 2018


The global hepatitis B vaccines market is estimated to be worth $997.0 million in 2010, and is forecast…

Anti-viralsGlaxoSmithKlineMarkets & MarketingMerck & CoPharmaceuticalVaccines

Important decision for the biotech industry from UK Supreme Court


The UK’s Supreme Court yesterday gave guidance on the patentability of gene sequence inventions,…

BenlystaBiotechnologyEli LillyEuropeGlaxoSmithKlineHuman Genome SciencesLegalPatentsPharmaceutical

6601 to 6625 of 7008 results

Back to top